Morning Overview on MSN
FDA says "manipulated" data backed approval, moves to withdraw the drug
The FDA has moved to pull Tavneos (avacopan) from the U.S. market, alleging that manipulated clinical trial data propped up ...
The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...
MedPage Today on MSN
FDA Claims 'Manipulated' Data Led to Drug's Approval, Proposes Withdrawal
Pivotal trial on avacopan was negative before actions of unblinded study personnel, agency ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –– Approval received in advance of ...
Stoboclo and Osenvelt were approved as interchangeable biosimilars for bone loss conditions, potentially reducing costs and increasing access. Darzalex Faspro was approved for high-risk smoldering ...
The Food and Drug Administration is asking Eli Lilly to gather more safety data on its new weight loss pill, Foundayo, including whether it could be linked to liver and heart problems, according to ...
April 14 (Reuters) - The U.S. Food and Drug Administration has asked Eli Lilly (LLY.N), opens new tab for more data on liver injury linked to its newly approved obesity pill, according to a letter ...
U.S. regulators have withdrawn their approval of a GSK Plc drug that the Trump administration had promoted as a treatment for autism, adding another twist to the unusual story of a decades-old drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results